Hypotension News and Research

RSS

$Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction$

Empagliflozin reduces risk of death in patients with heart failure and reduced ejection fraction

Empagliflozin reduces the risk of cardiovascular death or hospitalization for heart failure in patients with heart failure and a reduced ejection fraction.

31 Aug 2020

Ciliary proteins play vital role in cardiovascular functions and genetic diseases

Research from Chapman University provides new insight into the characteristics of crucial proteins within the ciliary membrane that play vital roles in human genetic diseases and cardiovascular functions.

20 Aug 2020

Study: Individuals who feel dizzy when they stand up may have an increased risk of dementia

Some people who feel dizzy or lightheaded when they stand up may have an increased risk of developing dementia years later, according to a new study published in Neurology®, the medical journal of the American Academy of Neurology.

7 Aug 2020

Ten major risk factors for Alzheimer's disease

Researchers have collated available scientific evidence on risk factors associated with Alzheimer's disease and come up with a list of ten important ones.

21 Jul 2020

New guideline can help clinicians identify hard-to-diagnose acute aortic syndrome

A new guideline aimed at helping clinicians identify the difficult-to-diagnose acute aortic syndrome is published in CMAJ (Canadian Medical Association Journal).

20 Jul 2020

Novel biomarkers required to triage and monitor severely ill COVID-19 patients

Diagnostics company SphingoTec GmbH ("sphingotec") announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec's diagnostic solutions for acute and critical care in supporting the triage, diagnosis, and management of severely ill COVID-19 patients.

18 Jun 2020

Does interferon therapy work in COVID-19?

A new study published on the preprint site medRxiv in May 2020 reports on the efficacy of interferons in treating COVID-19. The research could help evaluate the place of such therapy in the management of this disease.

2 Jun 2020

Meta-analysis of latest second-line treatments for status epilepticus

Status epilepticus (SE) is the most common neurologic emergency, with rates estimated between 1.3 and 81 cases per 100,000 people per year.

27 May 2020

Remdesivir shows promise in post-infection treatment for COVID-19 disease

The coronavirus disease (COVID-19) has no approved treatment or vaccine as the world grapple with its wrath. The viral infection has so far infected 1.8 million and killed more than 114,000 people. Now, a team of scientists has shown that an experimental antiviral drug, remdesivir, has shown promise in treating patients with severe COVID-19.

13 Apr 2020

Investigational drug vericiguat benefits patients with worsening heart failure

Patients with worsening heart failure and reduced ejection fraction who received the investigational drug vericiguat had a significantly lower rate of cardiovascular death or heart failure hospitalization compared with those receiving a placebo, based on research presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology.

30 Mar 2020

What does COVID-19 do to the body?

The novel coronavirus SARS-CoV-2, also known as 2019-nCoV, is the virus that causes COVID-19, and that is spreading throughout the world is causing panic in almost all countries. With a death rate ranging from 1% to 2% in young patients but about 5%-8% in elderly and sick patients, it is capable of ravaging multiple organ systems in the human body.

12 Mar 2020

Sphingotec’s bio-ADM can reliably support physicians in identifying high-risk sepsis patients

Diagnostics company SphingoTec GmbH today reported on new data on the utility of endothelial function biomarker bioactive Adrenomedullin

5 Mar 2020

Revolutionary, portable device can provide continuous blood pressure measurements

Researchers at Monash University are on the verge of creating a revolutionary, portable blood pressure monitoring device that can provide data continuously to patients from the comfort of their home.

31 Jan 2020

OH not linked with greater risk of adverse events among patients undergoing hypertension treatment

Orthostatic hypotension (OH), a drop in blood pressure after standing, is common among older adults and has been reported to be an important predictor of falls and fainting, as well as cardiovascular disease.

27 Jan 2020

Study sets the record straight on unproven therapy to treat sepsis

The Jan. 17 issue of the Journal of the American Medical Association features an important study about sepsis with an accompanying editorial by a University of Nebraska Medical Center expert.

17 Jan 2020

Antipsychotics linked to higher risk of head, brain injuries among persons with Alzheimer's

The use of antipsychotics is associated with increased risks of head and brain injuries among persons with Alzheimer's disease, according to a recent study from the University of Eastern Finland. The risk increase was highest at the initiation of antipsychotic use.

16 Jan 2020

Trial comparing three drugs for status epilepticus

Status epilepticus is a condition that is characterized by repeated seizures and is a medical emergency. Treatment is usually with a Benzodiazepine such as Diazepam or Lorazepam etc. There have been not any studies that look at the comparative benefit of drugs that could be prescribed for those who do not respond to the benzodiazepines. The study titled, “Randomized Trial of Three Anticonvulsant Medications for Status Epilepticus,” was published in the latest issue of the journal New England Journal of Medicine.

1 Dec 2019